Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02684279 · ClinicalTrials.gov registry record · Phase 3
Dasotraline Binge Eating Disorder Extension Study
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 533
- Enrollment target
NCT02684279: Completed Phase 3 study, sponsored by Sumitomo Pharma America.
NCT02684279 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 533 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02684279, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 533 participants
- Enrollment target
Study Summary
Binge Eating Disorder Extension Study.
Primary Outcome
Columbia-suicide severity rating scale (C-SSRS) Severity of suicidal ideation is rated on a 6-point scale from 0='No ideation present' to 5='Active ideation with plan and intent'. A score of 4 or 5 on this scale indicates serious suicidal ideation. Suicidal behavior is collected as presence/absence of actual attempts, non-suicidal self-injurious behavior, interrupted attempts, aborted attempts, preparatory acts or behavior, and any suicidal behavior
Interventions
- DRUG Dasotraline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 533 participants |
| Start Date | 2016-02-29 |
| Est. Completion | 2019-06-24 |
| Phase | Phase 3 |
What the finished NCT02684279 record still lists
NCT02684279 is an interventional study that assigns participants to a tested intervention. The registered 533 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 1 intervention - of which Dasotraline is the first listed.
NCT02684279 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02684279 about?
NCT02684279 is a clinical study titled "Dasotraline Binge Eating Disorder Extension Study". Binge Eating Disorder Extension Study.
What is the current status of trial NCT02684279?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 533 participants. The study started on 2016-02-29. Estimated completion is 2019-06-24.
What interventions are being tested in trial NCT02684279?
The interventions under investigation include: Dasotraline (DRUG).
Who is sponsoring clinical trial NCT02684279?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02684279's enrollment target sits among peer trials
533 704th of 2000 higher than 1,297 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05793151 · 532 participants · NA
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- NCT06378866 · 532 participants · Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI